Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

Documenti analoghi

• Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study
  di: Alba López‐Bravo, et al.
  Pubblicazione: (2025)
• A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study
  di: Jeffrey D. Sharon, et al.
  Pubblicazione: (2024)
• Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
  di: Richard B. Lipton, et al.
  Pubblicazione: (2025)
• Efficacy of galcanezumab in proline‐rich transmembrane protein 2 ( PRRT2 ) ‐associated familial hemiplegic migraine: A case series
  di: Costanza Sottani, et al.
  Pubblicazione: (2024)
• Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study
  di: Shivang Joshi, et al.
  Pubblicazione: (2026)